All lobbying filings

THE MCMANUS GROUP

Lobbying for BRISTOL-MYERS SQUIBB · Biopharmaceutical Company

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$80,000.00

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act

Lobbying activity 2

Medicare/Medicaid

Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act Issues related to Center for Medicare and Medicaid Innovation (CMMI) guardrails

Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.